Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

Massimo Filippi; Jerry S. Wolinsky; Giancarlo Comi

doi:10.1016/s1474-4422(06)70327-1

Article2008

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Giacomo P. Comi, Annalisa Pulizzi, Marco Rovaris, Oded Abramsky, T. Arbizu, А. Н. Бойко, Ralf Gold, Eva Havrdová, Sámuel Komoly, Krzysztof Selmaj, Basil Sharrack, Massimo Filippi

Article2007

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

Marco Rovaris, Giancarlo Comi, Maria A. Rocca, Paola Valsasina, David Ladkani, E Pieri, S. Weiss, Galia Shifroni, J. S. Wolinsky, Massimo Filippi, European Canadian Glatiramer Acetate Study Group

Article2003

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials

Filippo Martinelli Boneschi, Marco Rovaris, Kenneth P. Johnson, Aaron Miller, Jerry S. Wolinsky, David Ladkani, Galia Shifroni, Gıancarlo Comı, Massimo Filippi

Article2025

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study

David Kavanagh, Andrew S. Bomback, Marina Vivarelli, Carla Nester, Giuseppe Remuzzi, Ming Zhao, Edwin Wong, Yaqin Wang, Ipsita Krishnan, Imelda Schuhmann, Angelo J. Trapani, Nicholas J.A. Webb, Matthias Meier, Rubeen Israni, Richard J. Smith, A Ramos Espinosa, Rita Marcela Fortunato, Mari Mar Freijo, Nadia Viviana Fretes, Pablo Raffaele, Gianna Mastroianni Kirsztajn, Juliana Mansur Siliano,

Article2010

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study

Giancarlo Comi, Oded Abramsky, Txomin Arbizu, Ralf Gold, Eva Havrdová, Sámuel Komoly, Krzysztof Selmaj, Basil Sharrack, Massimo Filippi

Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study

Discussion(0)

Related publications

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials

Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study

Oral laquinimod in patients with relapsing-remitting multiple sclerosis: 36-week double-blind active extension of the multi-centre, randomized, double-blind, parallel-group placebo-controlled study